Predictive Oncology Inc. has decided to stop merger discussions with Renovaro Inc., clarifying that no binding agreement was made despite Renovaro's claims. The letter of intent for the merger, initially entered on January 1, 2025, was terminated on March 31, 2025, and POAI will focus on its core business in AI-driven drug discovery.